



March 5, 2020  
Company Name: AnGes Inc.  
Presentative: Ei Yamada, President & CEO  
(Code Number 4563, Mothers of the TSE)

## **AnGes and Osaka University launch joint DNA vaccine development against Coronavirus Disease 2019 (COVID-19)**

Tokyo, March 5, 2020 - AnGes Inc. announced starting development of a prophylactic DNA vaccine to combat Coronavirus 2019 in cooperation with Osaka University based the experience of launching plasmid DNA products for HGF gene therapy.

<Development of prophylactic DNA vaccine for Coronavirus 2019 using plasmid DNA production technology>

- Starting joint development of DNA vaccines for Coronavirus 2019 prevention with Osaka University with utilizing of the experience of plasmid DNA products development (products for HGF gene therapy).
- DNA vaccine production can realize to shorten its production period with comparing with using attenuated vaccine and recombinant virus protein.
- TAKARA BIO Inc. takes the responsibility of vaccine production with their plasmid DNA manufacturing experience in their production facilities.

<About DNA vaccine>

DNA vaccines are safe and can be produced in a short time period without using any dangerous pathogens. By inoculating a circular DNA (plasmid) encoding the protein of the target pathogen, the pathogen protein is produced in the body and immunized against the pathogen. Unlike attenuated vaccines, DNA vaccines are safe as they have no pathogenicity.

The impact this will have on the full-year consolidated results for this fiscal year is currently being examined.

<p>AnGes, Inc. Public Relations &amp; Investor Relations Group Contact: <a href="https://www.anges.co.jp/en/contact/">https://www.anges.co.jp/en/contact/</a></p>
---